Aim:  To study the prevalence of rheumatic disorders in two Aboriginal populations on the western coast of Cape York Peninsula. Methods:  Physical and radiological examination of 217 adult Aborigines at Aurukun Aboriginal Mission and 71 Aboriginal adults at Weipa Mission. The study was performed in October 1965. Results:  Mild to moderate degenerative arthritis was not uncommon in the populations examined. However, generalised or nodal osteoarthritis was not seen. One young woman had definite sero‐positive rheumatoid arthritis. This woman's appearance suggested some Torres Strait Islander influence. No case of gouty arthritis or classical ankylosing spondylitis was encountered. An incidental finding of retrospective interest was that the calculated body mass index showed that the majority of adults were underweight by Caucasian standards. Conclusions:  These findings are of historic interest given the health impacts of social, cultural and environmental circumstances of Aborigines currently reported.

SUMMARY A careful selection of 19 patients fitting the classical description of polymyalgia rheumatica have been examined by arthroscopy and thoroughly screened and followed up to exclude rheumatoid arthritis and other disease processes. Synovitis of the shoulder joint has been observed through the arthroscope in 17 and synovitis of varying degrees noted histologically, 4 of whom were studied by immunofluorescence. Five patients had radioactive joint scans.

No abstract

No abstract

BackgroundThe live attenuated tetravalent dengue vaccine (CYD-TDV) is licensed using a 0-, 6- and 12-month schedule in dengue-endemic areas. An effective shorter schedule may provide more rapid, optimal protection of targeted populations during vaccine campaigns in dengue-endemic countries. We compared immune responses to two schedules of CYD-TDV in a non-endemic population. We also evaluated the impact of yellow fever (YF) co-administration.MethodsThis phase II, open-label, multicentre study enrolled 390 healthy 18–45-year-olds in the USA with no prior exposure to dengue. Participants were randomised (4:4:4:1) to four treatment groups stratified by prior YF vaccine status: Group 1, CYD-TDV standard 0–6–12 months schedule; Group 2, CYD-TDV accelerated 0–2–6 months schedule; Group 3, CYD-TDV accelerated schedule with YF co-administered (dose 1); Group 4, YF vaccination only. Neutralising antibody geometric mean titres (GMTs) and percentages of seropositive participants (antibody titres ≥10 [1/dil]) were measured against each dengue serotype using a 50% plaque reduction neutralisation test.ResultsOn D28 post-CYD-TDV dose 3, there were no marked differences in seropositivity rates and GMTs between Groups 1 and 2. In Groups 1 and 2 respectively, 73.4 and 82.4% were dengue seropositive for ≥3 serotypes, with 50.0 and 42.6% seropositive against all four serotypes. Flavivirus status (FV+ or FV−) at baseline did not markedly affect GMTs and seropositivity rates with either schedule. In Groups 1 and 2, GMTs measured 6 months after the third dose decreased against all serotypes, except for a small increase in GMT for serotype 4 in Group 1. In addition, dengue seropositivity remained above 70% for serotypes 2, 3 and 4 in Groups 1 and 2. Co-administration with YF did not affect antibody responses against dengue and YF or impact vaccine safety following completion of the compressed schedule, compared to dengue or YF vaccination alone.ConclusionsThe live attenuated CYD-TDV vaccine given in a compressed schedule in a non-endemic setting can elicit similar antibody responses to the licensed CYD-TDV schedule.Trial registrationThis trial was registered on cinicaltrials.gov, NCT01488890 (December 8, 2011).Electronic supplementary materialThe online version of this article (10.1186/s12879-018-3389-x) contains supplementary material, which is available to authorized users.